President Trump has returned from his holiday in Florida and is officially back to work. Congress is back in session tomorrow and there is a lot to get done. Lawmakers will be voting on many items like immigration, disaster relief, and more. Will the two sides of the aisle be able to work together, or will divisions hinder Washington? Colby Hall is the managing editor at Mediate. He joins Cheddar to explain what agenda items will immediately be addressed. Washington is looking to tackle the issue of immigration with the Dreamers Act. There is also a disaster relief bill on the table that could be record-breaking. And of course, passing an official budget deal. Hall notes the importance passing these legislative measures could have on the midterm election. We are 308 days away from the midterm elections, and it will be a race to determine whether Republicans hold onto their majority in Congress.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More